Does the aMAP risk score predict mortality for patients with Alcoholic Liver Disease?
The age–male–ALBI–platelets (aMAP) risk score is an emerging tool used to assess the severity of liver fibrosis and other conditions. Researchers are investigating how this score relates to patient outcomes in various types of liver disease, including those caused by alcohol use.
What the research says
A study using data from the National Health and Nutrition Examination Survey (NHANES) found that higher aMAP scores are associated with increased mortality for patients with alcohol-related liver disease (ALD). The research showed a non-linear relationship between the aMAP score and all-cause mortality across different types of steatotic liver disease, which includes ALD 2.
While the aMAP score is used to help stratify risk in these populations, other factors also impact outcomes. For example, some studies suggest that certain medications can lower the risk of alcoholic liver disease and all-cause mortality over time 4. Additionally, research into gut microbiome health continues as scientists look for better ways to predict and manage conditions like ALD 6.
What to ask your doctor
- What is the aMAP risk score, and how is it used to assess my liver health?
- How does my specific aMAP score relate to my personal risk of complications from alcoholic liver disease?
- Are there other biomarkers or scores you use to monitor my liver condition?
- Based on my current results, what are the primary factors influencing my long-term outlook?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.